Augmented pulmonary vascular and venous constrictions to N G-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension

Pharmacology

Volumn 69, Issue 3, 2003, Pages 164-170

  Leung, Susan W S ^a   Cheng, Xing ^a   Lim, Su Lin ^a   Pang, Catherine C Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blood pressure; Cardiac output; Nitric oxide; Pulmonary vascular resistance; Pyrrolizidine alkaloid; Systemic vascular resistance

Indexed keywords

MONOCROTALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HEART OUTPUT; HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG VEIN OBSTRUCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; RAT; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RESISTANCE;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0141649457     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072670     Document Type: Article

References (42)

1. Rees DD, Palmer RM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
2. G-nitro-L-arginine on autonomic nerve activity. Br J Pharmacol 1991;103:2004-2008.
3. G-nitro-L-arginine methyl ester in vitro and in vivo. J Pharmacol Exp Ther 1993;267:1091-1099.
4. G-nitro-L-arginine methyl ester, sodium nitroprusside and noradrenaline on venous return in the anaesthetized cat. Br J Pharmacol 1993;108:933-940.
5. G-nitro-L-arginine methyl ester (L-NAME) of resistance to venous return in rats. Br J Pharmacol 1995;114:1454-1458.
6. Robertson BE, Warren JB, Nye PCG: Inhibition of nitric oxide synthesis potentiates hypoxic vasoconstriction in isolated rat lungs. Exp Physiol 1990;75:255-257.
7. Barer G, Emery C, Stewart A, Bee D, Howard P: Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats. J Physiol 1993;463:1-16.
8. + channel openers, aprikalim and pinacidil, on hypoxic pulmonary vasoconstriction. Eur J Pharmacol 1993;263:17-23.
9. MacLean MR, McCulloch KM: Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries: Effect of chronic hypoxia. Br J Pharmacol 1998;123:991-999.
10. Archer SL, Tolines JP, Raij L, Weir EK: Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium-derived relaxing factor. Biochem Biophys Res Commun 1989;164:1198-1205.
11. 2 responses in calf pulmonary resistance arteries. Am J Physiol 1992;262:L560-L565.
12. G-nitro-L-arginine methyl ester on hypoxic pulmonary vasoconstriction. Eur J Pharmacol 2000;402:111-117.
13. Hampl V, Archer SL, Nelson DP, Weir EK: Chronic EDRF inhibition and hypoxia: Effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993;75:1748-1757.
14. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JS, Fishman MC, Zapol WM: Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS-3) gene. Circ Res 1997;81:34-41.
15. Xue C, Rengasamy A, Le Cras RD, Koberna PA, Dailey GC, Johns RA: Distribution of NOS in normoxic vs. hypoxic rat lung: Upregulation of NOS by chronic hypoxia. Am J Physiol 1994;267:L667-L678.
16. Resta TC, Chicoine LG, Omdahl JL, Walker BR: Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol 1999;276:H699-H708.
17. Igari H, Tatsumi K, Sugito K, Kassahara Y, Saito M, Tani T, Kimura H, Kuriyama T: Role of EDRF in pulmonary circulation during sustained hypoxia. J Cardiovasc Pharmacol 1998;31:299-305.
18. A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation 1998;97:2169-2174.
19. Nakazawa H, Hori M, Ozaki H, Karaki H: Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol 1999;128:1098-1104.
20. Mathew R, Zeballos GA, Tun H, Gewitz MH: Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995;30:739-746.
21. Morita K, Ogawa Y, Tobise K: Effect of endothelium of pulmonary artery vasoreactivity in monocrotaline-induced pulmonary hypertensive rats. Jap Circ J 1996;60:585-592.
22. Gout B, Quiniou MJ, Khandoudi N, Le Dantec C, Saiag B: Impaired endothelium-dependent relaxation by adrenomedullin in monocrotaline-treated rat arteries. Eur J Pharmacol 1999;380:23-30.
23. Ito K, Nakashima T, Murakami K, Murakami T: Altered function of pulmonary endothelium following monocrotaline-induced lung vascular injury in rats. Br J Pharmacol 1988;94:1175-1183.
24. Yan CC, Huxtable RJ: Quantitation of the hepatic release of metabolites of the pyrrolizidine alkaloid, monocrotaline. Toxicol Appl Pharmacol 1994;127:58-63.
25. Yan CC, Huxtable RJ: The relationship between the concentration of the pyrrolizidine alkaloid monocrotaline and the pattern of metabolites released from the isolated liver. Toxicol Appl Pharmacol 1995;130:1-8.
26. Yan CC, Huxtable RJ: Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat. Biochem Pharmacol 1996;51:375-379.
27. Comini L, Bachetti T, Gaia G, Pasini E, Agnoletti L, Pepi P, Ceconi C, Curello S, Ferrari R: Aorta and skeletal muscle NO synthase expression in experimental heart failure. J Mol Cell Cardiol 1996;28:2241-2248.
28. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR: Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 1997;272:H806-H813.
29. 1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 2001;43:265-273.
30. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF: Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol 1999;276:L297-L303.
31. 1-receptor agonist. Br J Pharmacol 2000;129:853-858.
32. Wilson DW, Segall HJ, Pan LC, Dunston SK: Progressive inflammatory and structural changes in pulmonary vasculature of monocrotaline-treated rats. Microvasc Res 1989;38:57-80.
33. Lafranconi WM, Huxtable RJ: Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochem Pharmacol 1984;33:2479-2484.
34. Molteni A, Ward WF, Tsao CH, Port CD, Solliday NH: Monocrotaline-induced pulmonary endothelial dysfunction in rats. Exp Biol Med 1984;176:88-94.
35. Hoorn CM, Wagner JG, Roth RA: Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium. Toxicol Appl Pharmacol 1993;120:280-287.
36. Thomas HC, Lame MW, Dunston SK, Segall HJ, Wilson DW: Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol Appl Pharmacol 1998;151:236-244.
37. Pang CCY: Measurement of body venous tone. J Pharmacol Methods 2000;44:341-360.
38. Krowka MJ: Hepatopulmonary syndromes. Gut 2000;46:1-4.
39. Krowka MJ: Pulmonary hypertension: Diagnostics and therapeutics. Mayo Clin Proc 2000;75:625-630.
40. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ: Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985;88:1050-1054.
41. Yeong ML, Swinburn B, Kennedy M, Nicholson G: Hepatic veno-occlusive disease associated with comfrey ingestion. J Gastroenterol Hepatol 1990;5:211-214.
42. Steenkamp V, Stewart MJ, Zuckerman M: Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit 2000;22:302-306.